FY26 Preliminary Final Report
Filed with ASX · · 45 pages · English
Summary by 6ix AI
The report highlights a significant underlying loss after tax, although revenue from continuing operations showed a slight increase compared to the previous year. The company is focused on improving its pathology services and has implemented cost management strategies to enhance operational efficiency. Healius continues to invest in digital technologies to support productivity and service quality across its pathology network.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Healius
- Healius transitions pathology arrangements with Ramsay
- FY26 trading update and strategic review of assets
- Healius announces 1H 2026 results
- Half Yearly Report and Accounts
- Half Year 2026 Results Presentation
Later from Healius
- FY26 Results Release
- FY26 Results Presentation
- S&P DJI Announces September 2026 Quarterly Rebalance
- Agreement to sell Agilex Biolabs to Novotech
Follow Healius into a list and get an email when it puts out news.
Follow Healius